LONDON - Astex Therapeutics Ltd. landed a $520 million deal with Novartis AG for three cell-cycle inhibitors, the largest advertised figure for any deal involving a UK biotech to date, and bringing the total potential value of licenses granted by Astex in the past year to more than $1 billion. (BioWorld International)
LONDON - Astex Therapeutics Ltd. landed a $520 million deal with Novartis AG for three cell-cycle inhibitors, the largest advertised figure for any deal involving a UK biotech to date, and bringing the total potential value of licenses granted by Astex in the past year to more than $1 billion. (BioWorld Today)
LONDON - Domantis Ltd. sealed a multiproduct deal with Bristol-Myers Squibb Co. for its domain antibodies (dAb) worth $9.2 million in up-front and research payments, plus $20 million per dAb in preclinical and clinical milestones, plus royalties on sales. The aim is to discover and develop dAbs against T-cell co-stimulation targets that cannot be hit by conventional antibodies. (BioWorld Today)
LONDON - Domantis Ltd. sealed a multiproduct deal with Bristol-Myers Squibb Co. for its domain antibodies (dAb) worth $9.2 million in up-front and research payments, plus $20 million per dAb in preclinical and clinical milestones, plus royalties on sales. The aim is to discover and develop dAbs against T-cell co-stimulation targets that cannot be hit by conventional antibodies. (BioWorld Today)
